In the NASH murinemodel study, Zhang et al. 13showed that WAY-362450, an FXR agonist, decreased AST function and ALT values.According to the published preliminary results of the phase-2 placebo-controlledstudy with Cilofexor (an FXR agonist) in PBC patients, AST, ALT, GGT and ALP serumlevels were effectively reduced14. This evidence concerns the gene NR1H4 and primary biliary cholangitis.